Bacterial Vaccines and Therapies - Building a Product Pipeline

细菌疫苗和疗法 - 建立产品线

• 批准号: 700096
• 金额: $ 3.19万
• 依托单位: ABSYNTH BIOLOGICS LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Market
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=700096
• 关键词: Bacterial; Vaccines; Therapies; Building; Product

Absynth Biologics has successfully demonstrated an innovative approach for developing newantibacterial vaccines and antibodies. Absynth’s technology identifies proteins, essential forthe life of bacteria that harness the immune system. To date the Company has shown itsapproach can protect against infections caused by a major pathogen Staphylococcus aureus (S.aureus), including antibiotic resistant variety MRSA (Methicillin Resistant S. aureus). TheAbsynth anti-S.aureus vaccine and antibodies are being advanced in pre-clinical development.A central aspect of the Absynth technology is the degree of conservation of these proteinsacross the bacterial kingdom. Consequently the same targets found in S. aureus also arepresent in many other bacterial pathogens. With this proprietary knowledge Absynth canrapidly initiate new vaccine and antibody programmes to develop a product pipeline.The objective of this project is to assess the broader market needs to prevent and treatbacterial infections, addressable by Absynth’s technology. With a clear understanding ofunmet customer/patient needs, market size, drivers, dynamics and competition, Absynth willbe able to select those opportunities to build a pipeline.Resistance to antibiotics in increasing at an alarming rate, driving the need for antibacterialvaccines and antibodies. The market for bacterial vaccines is expected to grow from $3.9billion to $15.5 billion by 2014 and there is growing interest in anti-infective antibodyproducts with only one, Synagis, licensed for use.There currently are no marketed S. aureus vaccines or antibodies and the sales potential isestimated to be >US $2 billion. Many other bacterial infections lack vaccines or antibodiesincluding hospital infections cause by C. difficile, sexually transmitted diseases caused by N.gonorrhoea and community-based infections caused by E. coli. The new opportunities forAbsynth are significant.

Absynth Biologics已经成功地展示了一种开发新型抗菌疫苗和抗体的创新方法。Absynth的技术识别蛋白质，这些蛋白质对利用免疫系统的细菌的生命至关重要。迄今为止，该公司已经证明其方法可以防止由主要病原体金黄色葡萄球菌（金黄色葡萄球菌）引起的感染，包括耐抗生素品种MRSA（耐甲氧西林金黄色葡萄球菌）。TheAbsynth anti-S。金黄色葡萄球菌疫苗和抗体的临床前开发正在取得进展。Absynth技术的一个核心方面是这些蛋白质在细菌界的保存程度。因此，在金黄色葡萄球菌中发现的相同靶标也存在于许多其他细菌病原体中。凭借这些专有知识，Absynth可以快速启动新的疫苗和抗体计划，以开发产品线。该项目的目的是评估更广泛的市场需求，以预防和治疗细菌感染，Absynth的技术可以解决。随着对未满足的客户/患者需求、市场规模、驱动因素、动态和竞争的清晰了解，Absynth将能够选择这些机会来建立管道。对抗生素的耐药性正以惊人的速度增长，推动了对抗菌疫苗和抗体的需求。到2014年，细菌疫苗市场预计将从39亿美元增长到155亿美元，人们对抗感染抗体产品的兴趣越来越大，只有一种抗感染抗体产品Synagis获得了使用许可。目前还没有上市的金黄色葡萄球菌疫苗或抗体，其销售潜力估计为100亿至20亿美元。许多其他细菌感染缺乏疫苗或抗体，包括艰难梭菌引起的医院感染、淋病奈瑟菌引起的性传播疾病和大肠杆菌引起的社区感染。absynth的新机遇意义重大。